Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy
Open accessAbstract
BACKGROUND Aberrant activation of Wnt/β-catenin has been shown to promote ovarian cancer proliferation and chemoresistance. Pyrvinium, an FDA-approved anthelmintic drug, has been identified as a potent Wnt inhibitor. Pyrvinium may sensitize ovarian cancer cells to chemotherapy. MATERIAL AND METHODS The effect of pyrvinium alone and its combination with paclitaxel in ovarian cancer was investigated using an in vitro culture system and in vivo xenograft models. The mechanisms of its action were also analyzed, focusing on the Wnt/β-catenin pathway. RESULTS Pyrvinium inhibited growth and induced apoptosis of paclitaxel- and cisplatin-resistant epithelial ovarian cancer cell lines A2278/PTX and SK-OV-3. Its combination with paclitaxel was synergistic in targeting ovarian cancer cells in vitro. In 3 independent ovarian xenograft mouse models, pyrvinium alone inhibited tumor growth. More importantly, we observed significant inhibition of tumor growth throughout the treatment when using pyrvinium and paclitaxel combined. Mechanistically, pyrvinium increased the Wnt-negative regulator axin and decreased the b-catenin levels in ovarian cancer cells. In addition, pyrvinium suppressed Wnt/b-catenin-mediated transcription, as shown by the decreased mRNA levels of MYC, cyclin D, and BCL-9. In contrast, the inhibitory effects of pyrvinium were reversed by β-catenin stabilization or overexpression, demonstrating that pyrvinium acted on ovarian cancer cells via targeting the Wnt/β-catenin signaling pathway. CONCLUSIONS We demonstrated that the anthelmintic drug pyrvinium targets ovarian cancer cells through suppressing Wnt/β-catenin signaling. Our work highlights the therapeutic value of inhibiting Wnt/β-catenin in ovarian cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PP is a well-known inhibitor of the Wnt/β-catenin pathway.
“PP is a well‐known inhibitor of the Wnt/β‐catenin pathway [41, 43]”
From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in <scp>2D</scp> and <scp>3D</scp> Cell Culture Models (2024) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854 · see citing works
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B. T., & Mills, G. B. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2644 · Cited by 1,362 · see citing works
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1123 · Cited by 1,155 · see citing works
Zebrafish Prickle, a Modulator of Noncanonical Wnt/Fz Signaling, Regulates Gastrulation Movements
Veeman, M. T., Slusarski, D. C., Kaykas, A., Louie, S. H., & Moon, R. T. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00240-9 · Cited by 945 · see citing works
Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang‐Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., & Ozols, R. F. (1987) · PubMed · Cited by 501 · see citing works
Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α
Thorne, C. A., Hanson, A. J., Schneider, J., Tahinci, E., Orton, D., Cselenyi, C. S., Jernigan, K. K., Meyers, K. C., Hang, B. I., Waterson, A. G., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.453 · Cited by 485 · see citing works
The Wnt/β-catenin pathway in ovarian cancer: A review
Arend, R. C., Londoño-Joshi, A. I., Straughn, J. M., & Buchsbaum, D. J. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.09.034 · Cited by 458 · see citing works
Osada, T., Chen, M., Yang, X. Y., Spasojevic, I., Vandeusen, J. B., Hsu, D., Clary, B. M., Clay, T. M., Chen, W., Morse, M. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3978 · Cited by 271 · see citing works
Su, H., Lai, H., Lin, Y., Liu, C. H., Chen, C., Chou, Y., Lin, S., Lin, W., Lee, H., & Yu, M. (2009) · International Journal of Cancer · doi:10.1002/ijc.25083 · Cited by 176 · see citing works
Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer
Arend, R. C., Londoño-Joshi, A. I., Samant, R. S., Li, Y., Conner, M., Hidalgo, B., Alvarez, R. D., Landen, C. N., Straughn, J. M., & Buchsbaum, D. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.04.005 · Cited by 161 · see citing works
Xu, L., ZHANG, L., HU, C., Liang, S., Fei, X., Yan, N., Zhang, Y., & Zhang, F. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3337 · Cited by 106 · see citing works
Kim, S., & Jho, E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.137471 · Cited by 91 · see citing works
Bodnar, L., Stanczak, A. M., Cierniak, S., Smoter, M., Cichowicz, M., Kozłowski, W., Szczylik, C. A., Wieczorek, M., & Lamparska‐Przybysz, M. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-16 · Cited by 80 · see citing works
Hua, W., Christianson, T. A., Rougeot, C., Rochefort, H., & Clinton, G. M. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00187-5 · Cited by 79 · see citing works
Pyrvinium Attenuates Hedgehog Signaling Downstream of Smoothened
Li, B., Fei, D. L., Flaveny, C. A., Dahmane, N., Baubet, V., Wang, Z., Bai, F., Pei, X., Rodríguez‐Blanco, J., Hang, B. I., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0317 · Cited by 76 · see citing works
Harada, Y., Ishii, I., Hatake, K., & Kasahara, T. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.12.034 · Cited by 71 · see citing works
Yu, D.-H., Macdonald, J. E., Liu, G., Lee, A. S., Ly, M., Davis, T. M. E., Ning, K., Zhou, D., Wong‐Staal, F., & Li, Q. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003951 · Cited by 70 · see citing works
Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974
Boone, J. D., Arend, R. C., Johnston, B. E., Cooper, S. J., Gilchrist, S. A., Oelschlager, D. K., Grizzle, W. E., McGwin, G., Gangrade, A., Straughn, J. M., et al. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.150 · Cited by 69 · see citing works
Li, B., Flaveny, C. A., Giambelli, C., Fei, D. L., Han, L., Hang, B. I., Bai, F., Pei, X., Nosé, V., Burlingame, O., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101969 · Cited by 65 · see citing works
Li, H., Jiao, S., Li, X., Banu, H., Hamal, S., & Wang, X. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.140 · Cited by 61 · see citing works
Pyrvinium targets autophagy addiction to promote cancer cell death
Deng, L., Lei, Y., Liu, R., Li, J., Yuan, K., Li, Y., Chen, Y., Liu, Y., Lü, Y., Edwards, C. K., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.142 · Cited by 59 · see citing works
Ishii, I., Harada, Y., & Kasahara, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00137 · Cited by 56 · see citing works
The Antihelmintic Drug Pyrvinium Pamoate Targets Aggressive Breast Cancer
Xu, W., Lacerda, L., Debeb, B. G., Atkinson, R. L., Solley, T. N., Li, L., Orton, D., McMurray, J. S., Hang, B. I., Lee, E. N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071508 · Cited by 47 · see citing works
Deng, Z., Wang, L., Hou, H., Zhou, J., & Xu, L. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3228 · Cited by 42 · see citing works
Xiao, M., Zhang, L., Zhou, Y., Rajoria, P., & Wang, C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.12.059 · Cited by 40 · see citing works
Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells
Barghout, S. H., Zepeda, N., Xu, Z., Steed, H. L., Lee, C., & Fu, Y. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.138 · Cited by 39 · see citing works
Han, X., DU, F., Jiang, L., Zhu, Y., Chen, Z., Liu, Y., Hong, T., WANG, T., Mao, Y., Wu, X., et al. (2013) · Oncology Letters · doi:10.3892/ol.2013.1568 · Cited by 26 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Targeting the Wnt/β-catenin signaling pathway in cancer
Zhang, Y., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00990-3 · Cited by 1,431 · see citing works
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734 · see citing works
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Chen, X., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, . (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 321 · see citing works
Nguyen, V. H. L., Hough, R., Bernaudo, S., & Peng, C. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0596-z · Cited by 220 · see citing works
Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance
Teeuwssen, M., & Fodde, R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101658 · Cited by 199 · see citing works
Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics
Harb, J., Lin, P., & Hao, J.-J. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0763-9 · Cited by 116 · see citing works
Activation of Wnt signaling promotes olaparib resistant ovarian cancer
Yamamoto, T. M., McMellen, A. N., Watson, Z. L., Aguilera, J., Ferguson, R. L., Nurmemmedov, E., Thakar, T., Moldovan, G., Kim, H., Cittelly, D. M., et al. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23064 · Cited by 95 · see citing works
Yang, X. H., Zhu, S., Li, L., Zhang, L., Xian, S., Wang, Y., & Cheng, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s152238 · Cited by 84 · see citing works
Wnt Signaling in Gynecologic Malignancies
McMellen, A. N., Woodruff, E. R., Corr, B. R., Bitler, B. G., & Moroney, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124272 · Cited by 66 · see citing works
Penfluridol overcomes paclitaxel resistance in metastatic breast cancer
Gupta, N., Gupta, P., & Srivastava, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41632-0 · Cited by 63 · see citing works
Shang, S., Yang, J., Jazaeri, A. A., Duval, A. J., Tufan, T., Fischer, N. L., Benamar, M., Guessous, F., Lee, I.-Y., Campbell, R. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0215 · Cited by 62 · see citing works
Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment
Pećina‐Šlaus, N., Aničić, S., Bukovac, A., & Kafka, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076733 · Cited by 51 · see citing works
Xiao, S., Li, Y., Pan, Q., Ye, M., He, S., Tian, Q., & Xue, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26865 · Cited by 50 · see citing works
Dattilo, R., Mottini, C., Camera, E., Lamolinara, A., Auslander, N., Doglioni, G., Muscolini, M., Tang, W., Planque, M., Ercolani, C., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1184 · Cited by 47 · see citing works
Zhao, Y., Tian, B., Wang, Y., & Ding, H. (2017) · Medical Science Monitor · doi:10.12659/msm.903552 · Cited by 48 · see citing works
Zhang, H., Hu, B., Wang, Z., Zhang, F., Wei, H., & Li, L. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3435-1 · Cited by 46 · see citing works
Duan, S., Dong, X., Hai, J., Jiang, J., Wang, W., Yang, J., Zhang, W., & Chen, C. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.044 · Cited by 45 · see citing works
Self-citationPyrvinium Pamoate: Past, Present, and Future as an Anti-Cancer Drug
Schultz, C. W., & Nevler, A. (2022) · Biomedicines · doi:10.3390/biomedicines10123249 · Cited by 41 · see citing works
El-Derany, M. O., & El‐Demerdash, E. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113942 · Cited by 36 · see citing works
Sun, Y., Wu, J., Dong, X., Zhang, J., Meng, C., & Liu, G. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100987 · Cited by 36 · see citing works
Zhao, X., Cheng, Z., & Wang, J. (2018) · Medical Science Monitor · doi:10.12659/msm.911194 · Cited by 35 · see citing works
Li, H., Liu, S., Jin, R., Xu, H., Li, Y., Chen, Y., & Zhao, G. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00654-2 · Cited by 34 · see citing works
Casein Kinase 1α as a Regulator of Wnt-Driven Cancer
Shen, C., Nayak, A., Meléndez, R. A., Wynn, D. T., Jackson, J., Lee, E. N., Ahmed, Y. F., & Robbins, D. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165940 · Cited by 30 · see citing works
Liu, Q., Zhao, Y., Xing, H., Li, L., Li, R., Dai, J., Li, Q., & Fang, S. (2018) · Gene · doi:10.1016/j.gene.2018.11.098 · Cited by 29 · see citing works
Miao, W., Lu, T., Liu, X., Yin, W., & Zhang, H. (2020) · Cancer Biomarkers · doi:10.3233/cbm-190640 · Cited by 29 · see citing works
Barbarino, M., Cesari, D., Intruglio, R., Indovina, P., Namagerdi, A. A., Bertolino, F. M., Bottaro, M., Rahmani, D., Bellan, C., & Giordano, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26579 · Cited by 23 · see citing works
Yang, L., Zhao, H., Yin, X., Liang, H., Zheng, Z. G., Shen, Q., & Hu, W. (2020) · PubMed Central · Cited by 23 · see citing works
Drug Repurposing Strategies for Non-cancer to Cancer Therapeutics
Singhal, S., Maheshwari, P., Krishnamurthy, P. T., & Patil, V. M. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220317140557 · Cited by 18 · see citing works
Cui, L., Zhao, J., & Liu, J. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.11.017 · Cited by 18 · see citing works
The LINC00922 aggravates ovarian cancer progression via sponging miR-361-3p
Wang, L., Ren, C., Xu, Y., Yang, L., Chen, Y., & Zhu, Y. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00828-7 · Cited by 18 · see citing works
Banos, G., Lindsay‐McGee, V., Desta, T. T., Bettridge, J., Sánchez-Molano, E., Vallejo‐Trujillo, A., Matika, O., Dessie, T., Wigley, P., Christley, R., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.543890 · Cited by 17 · see citing works
Chen, H., Liu, Y., Liu, P., Dai, Q., & Wang, P. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10662 · Cited by 16 · see citing works
RetractedLiu, Z., Zhang, R., Sun, Z., Yao, J., Yao, P., Chen, X., Wang, X., Gao, M., Wan, J., Du, Y., et al. (2020) · PeerJ · doi:10.7717/peerj.8670 · Cited by 16 · see citing works
Ponzini, F. M., Schultz, C. W., Leiby, B. E., Cannaday, S., Yeo, T., Posey, J., Bowne, W. B., Yeo, C., Brody, J. R., Lavu, H., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-073839 · Cited by 15 · see citing works
Menon, N. A., Kumar, C. D., Ramachandran, P., Blaize, B., Gautam, M., Cordani, M., & Kumar, L. D. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177137 · Cited by 14 · see citing works
Chemical genomics with pyrvinium identifies C1orf115 as a regulator of drug efflux
Masud, S. N., Chandrashekhar, M., Aregger, M., Tan, G., Zhang, X., Mero, P., Pirman, D. A., Zaslaver, O., Smolen, G. A., Lin, Z., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01109-0 · Cited by 13 · see citing works
Gu, H.-Z., Lin, R., Zheng, F., & ZHANG, Q. (2020) · Journal of Molecular Histology · doi:10.1007/s10735-020-09921-5 · Cited by 14 · see citing works
Ghahremani, H., Nabati, S., Tahmori, H., Peirouvi, T., Sirati‐Sabet, M., & Salami, S. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1804947 · Cited by 13 · see citing works
Yi, Y., Liao, B., Zheng, Z., Yang, X., Yang, Y., Zhou, Y., Tan, B., & Yang, X. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9803 · Cited by 13 · see citing works
Reposition of the anti-inflammatory drug diacerein in an in-vivo colorectal cancer model
Abdel‐Latif, R. T., Wadie, W., Abdel–Mottaleb, Y., Abdallah, D. M., El‐Maraghy, N. N., & El-Abhar, H. S. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.12.009 · Cited by 13 · see citing works
Faheem, S. A., El-Sayed, N. M., Moustafa, Y. M., Saeed, N. M., & Hazem, R. M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108538 · Cited by 13 · see citing works
Aberrant angiogenic signaling pathways: Accomplices in ovarian cancer progression and treatment
Zhou, W., Zeng, T., Chen, J., Tang, X., Yuan, Y., Hu, D., Zhang, Y., Li, Y., & Zou, J. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111240 · Cited by 12 · see citing works
Niiro, E., Morioka, S., Iwai, K., Yamada, Y., Ogawa, K., Kawahara, N., & Kobayashi, H. (2018) · Biomedical Reports · doi:10.3892/br.2018.1045 · Cited by 12 · see citing works
Booij, T. H., Leonhard, W. N., Bange, H., Yan, K., Fokkelman, M., Plugge, A. J., Veraar, K. A. M., Dauwerse, J. G., van Westen, G. J. P., van de Water, B., et al. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz029 · Cited by 12 · see citing works
Li, J., Jiang, Y., Wang, P., Ke, S., Yang, L., & Shen, Y. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000747 · Cited by 9 · see citing works
Targeting Wnt Signaling To Overcome PARP Inhibitor ResistancePreprint
Yamamoto, T. M., McMellen, A. N., Watson, Z. L., Aguilera, J., Sikora, M. J., Ferguson, R. L., Nurmemmedov, E., Thakar, T., Moldovan, G., Kim, H., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/378463 · Cited by 8 · see citing works
Serala, K., Bai, J., & Prince, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70222 · Cited by 6 · see citing works
Targeted treatment for craniopharyngioma
Stec, N. E., Barker, F. G., & Brastianos, P. K. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-04942-0 · Cited by 6 · see citing works
Wu, C. (2022) · Oncology Letters · doi:10.3892/ol.2022.13326 · Cited by 5 · see citing works
Drug resistance and immunotherapy in gynecologic cancers
Sarojamma, V., Bonala, S., Vadde, N. K., Natu, J. Z., Basha, R. R., Vadde, R., & Ahmad, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122104 · Cited by 5 · see citing works
Bellis, C., Mlaza, M., Ali, A. S., Abrahams, A., & Prince, S. (2025) · Biochemical Society Transactions · doi:10.1042/bst20241069 · Cited by 4 · see citing works
Amalia, D., Febriani, F., & Arfianti, A. (2025) · Iranian Biomedical Journal · doi:10.66224/ibj.5158 · Cited by 1 · see citing works
Repurposing antiparasitic drugs for the treatment of other diseases
Lashgari, N., Roudsari, N. M., Ahmadvand, D., Amirlou, D., Khales, S. D., Ahmadian, D., Momtaz, S., Abdolghaffari, A. H., Jamialahmadi, T., & Sahebkar, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15178-1.00005-5 · Cited by 1 · see citing works
Scarabelot, K. S., ANTUNES, M. M. U., Pelegrini, A., & Virtuoso, J. F. (2019) · Revista de Nutrição · doi:10.1590/1678-9865201932e180257
Introduction on Novel Treatment for Cancer Treatment
Moeinafshar, A., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_248-1
Faux, M. C., Ma, C., Kane, S. R., Samson, A. L., Hirokawa, Y., Priebe, I. K., Cosgrove, L. J., Singh, R., Christie, M., Brown, G. J., et al. (2025) · Organoids · doi:10.3390/organoids4030015
Introduction on Novel Treatment for Cancer Treatment
Moeinafshar, A., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_248
Additional file 5 of The LINC00922 aggravates ovarian cancer progression via sponging miR-361-3p
Wang, L., Ren, C., Xu, Y., Yang, L., Chen, Y., & Zhu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14773730
Additional file 1 of Targeting the Wnt/β-catenin signaling pathway in cancer
Zhang, Y., & Wang, X. (2020) · Figshare · doi:10.6084/m9.figshare.13336327
Additional file 6 of The LINC00922 aggravates ovarian cancer progression via sponging miR-361-3p
Wang, L., Ren, C., Xu, Y., Yang, L., Chen, Y., & Zhu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14773733
Additional file 3 of The LINC00922 aggravates ovarian cancer progression via sponging miR-361-3p
Wang, L., Ren, C., Xu, Y., Yang, L., Chen, Y., & Zhu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14773724
Additional file 2 of The LINC00922 aggravates ovarian cancer progression via sponging miR-361-3p
Wang, L., Ren, C., Xu, Y., Yang, L., Chen, Y., & Zhu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14773721
Additional file 1 of The LINC00922 aggravates ovarian cancer progression via sponging miR-361-3p
Wang, L., Ren, C., Xu, Y., Yang, L., Chen, Y., & Zhu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14773718
Additional file 4 of The LINC00922 aggravates ovarian cancer progression via sponging miR-361-3p
Wang, L., Ren, C., Xu, Y., Yang, L., Chen, Y., & Zhu, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14773727
Сигнальный путь Wnt и открытие лекарств. II. Низкомолекулярные ингибиторы Wnt/β-катенинового пути
Степанович, Х. Ю., Zaitsev, S., Tiasto, V., Митяева, А. М., Шодунке, О. К., & Степанович, Б. И. (2026) · Clinical and Fundamental Medicine · doi:10.24866/3033-5485/2026-2/58-100
- Authors
- Zhang, C., Zhang, Z., Zhang, S., Wang, W., & Hu, P.
- Affiliations
- Yangtze University (CN)
- Department of Obstetrics and Gynaecology, Jingzhou Third People’s Hospital, Jingzhou, Hubei, China (mainland)
- Corresponding author
- Hu, Ping
- Venue
- Medical Science Monitor
- Published
- 2017-01-16
- Volume
- 23
- Pages
- 266-275
- ISSN
- 1234-1010 (ISSN-L)
- 1643-3750
- PMC
- PMC5266205
- OpenAlex
- W2574659094
- Cited by
- 70
- References
- 27
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 12 · 2020: 18 · 2019: 9 · 2018: 8 · 2017: 3
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Medical Science Monitor (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yangtze University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- pyrvinium, Wnt/β-catenin signaling, ovarian cancer, chemosensitivity, paclitaxel, chemoresistance, Axin, β-catenin stabilization, c-Myc, cyclin D, apoptosis, xenograft tumor growth
- MeSH terms
- Animals, Anthelmintics, Antineoplastic Agents, Drug Synergism, Female, Humans, Ovarian Neoplasms, Pyrvinium Compounds, Mice, SCID, Apoptosis, Paclitaxel, Lithium Chloride, Drug Resistance, Neoplasm, Cell Line, Tumor, Cell Proliferation, beta Catenin, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
